Roche writes off ul­cer­a­tive col­i­tis por­tion of etrolizum­ab pro­gram, days af­ter dis­sect­ing PhI­II set­back

Af­ter dis­ap­point­ing Phase III read­outs all but dec­i­mat­ed Roche’s ex­pec­ta­tions for etrolizum­ab as an ul­cer­a­tive col­i­tis treat­ment, the phar­ma gi­ant is bury­ing the pro­gram in its quar­ter­ly cleanup rit­u­al.

Roche not­ed the change in its Q3 up­date, where it al­so dis­closed scrap­ping two Phase I pro­grams: RG6000, a DLK in­hibitor for ALS; and RG7861, an an­ti­body-an­tibi­ot­ic con­ju­gate against S.au­reus. Then there’s a dis­con­tin­u­a­tion for Po­livy, the Seagen-part­nered ADC tar­get­ing CD79b, in fol­lic­u­lar lym­phoma for “port­fo­lio pri­or­i­ties.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.